Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREAT-EC
NCT07605247Phase 2Not yet recruiting
- Sponsor
- Rutgers University
- Start
- Jun 2026
- Primary completion
- Jan 2028
- Modality
- Peptides, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of tirzepatide in endometrial cancer (EC), Endometrial intraepithelial neoplasia (EIN), sponsored by Rutgers University. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
03
Conditions
endometrial cancer (EC)Endometrial intraepithelial neoplasia (EIN)
Beyond the preview
Go deeper on NCT07605247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07605247.